AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03244657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conbercept ophthalmic injection （0.5mg）
Description: The target eye receives intravitreal injection of 0.5mg conbercept ophthalmic injection once every 12 weeks; if a subject meets additional drug administration criteria within 12 weeks between treatments, the subject can receive additional injection treatment
Study NCT03244657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conbercept ophthalmic injection （0.5mg）
Description: In principle, the first administration time of the target eye uses the time determined by the assessment at end of STAR study; later, based on treatment-extension drug administration criteria, an investigator determines next visit time/treatment interval according to assessment result at each visit.When a subject's visit/treatment interval extends to 12 weeks, an additional safety visit can be arranged if an investigator considers that there is suspicious active lesion; if assessment result at the safety visit meets additional drug administration criteria, additional injection treatment can be given.
Study NCT00480857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere)
Description: Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.
Study NCT00617305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil was administered at the dose previously established for each subject (not to exceed 40 mg per day) orally once daily. Tadalafil was supplied as 20-mg tablets.
Study NCT00998439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeQuent® Please
Description: * 6 F, 7 F, or 8 F guiding catheters have to be used~* after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~* additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~* Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~* ISR must be predilated with uncoated balloon~* balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~* inflation time has to be ≥ 30 sec~* select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~* each Paclitaxel-eluting balloon catheter is allowed for single use only~* additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~* if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug
Study NCT00998439 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SeQuent® II
Description: * 6 F, 7 F, or 8 F guiding catheters have to be used~* after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~* additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~* Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~* ISR must be predilated with uncoated balloon~* balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~* inflation time has to be ≥ 30 sec~* select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~* each Paclitaxel-eluting balloon catheter is allowed for single use only~* additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~* if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug
Study NCT00617305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil was administered at the dose previously established for each subject (not to exceed 40 mg per day) orally once daily. Tadalafil was supplied as 20-mg tablets.
Study NCT02329197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin (HCG)
Description: intrauterine injection of HCG prior to embryo transfer in an IVF cycle
Study NCT02258620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinitrate isosorbide
Description: dinitrate isosorbide (cedocard\*) by continuous intra venous (1 to 5 mg/h) dinitrate isosorbide (cedocard\*) 5 mg by intra arterial direct in the sheat
Study NCT02258620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitroglycerine
Description: nitroglycerine dermal patch 15 mg/24h : 67,2 mg/21 cm2
Study NCT01265056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: On Study day 1: 1200mg (single dose).~Study day 2,3: 300mg TID, 900mg daily.~Study day 4-7: 600mg TID 1800mg\* daily.~Study day 8-11: 800mg TID 2400mg\* daily \[Optional increase to 2400 if pain scores are still 4 on NRS\]~Study day 11: 1200mg TID 3600mg\* daily \[Optional increase to 3600 if pain scores are still >4 on NRS\]~\* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation.
Study NCT01265056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar Pill is administered similar to the protocol used for the investigational drug.
Study NCT01387633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact
Description: For family members/caregivers: telephone contacts will be conducted in day and time which family member/caregiver prefers, and he/she may make collect calls to the researcher always he/she judges it necessary during the period of study. Phone contacts will be recorded to ensure the registration of orientation given, using a digital phone recorder PCTEL. And they will be arranged with the technique of motivational interviewing that includes the skills to ask, listen and inform. For this, protocols based on these skills, which the covered topics will be those worked in group sessions through Diabetes Conversation Maps. Voice quality related to the tone, volume and clarity as well as the skills and strategies to listen to the interviews will be worked under the guidance of an audiologist
Study NCT01387633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention group for people with diabetes through Diabetes Conversation Maps
Description: For people with diabetes mellitus: educational interventions will be conducted in accordance with the assumptions of the Social Cognitive Theory, through Diabetes Conversation Maps , whose use is consistent with this theory (ADA, 2007). Diabetes Conversation Maps are a tool which involves people in the learning process about the disease, to make them able to process information more effectively and use them in making daily decisions in the management of diabetes mellitus (DM). It is recommended that this tool is used in small groups of three to ten people, in order to provide dynamic discussions among the participants (ADA, 2007). Currently, the maps that cover the following learning contexts: How the Body and Diabetes Work, Healthy Eating and Physical Activity, and Medication Treatment and Monitoring of Blood Glucose; Achieving the Goals with the Insulin and Weather Map of Diabetic Foot are available for the Brazilian Portuguese language.
Study NCT00801970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Treatment
Description: 15 weekly therapy sessions.
Study NCT00801970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Therapy
Description: 3 months of weekly group therapy sessions.
Study NCT03225456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: Intra-nasal oxytocin
Study NCT03225456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Intra-nasal placebo
Study NCT02711852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Administered as oral capsules
Study NCT00821509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disinfectant rubbing
Description: Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
Study NCT00473980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin, celecoxib, esomeprazole
Study NCT00473980 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Indomethacin, celecoxib, esomeprazole
Study NCT00807573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Day 1: Paclitaxel (90 mg/m\^2 over 60 minutes) Day 15: Paclitaxel (90 mg/m\^2 over 60 minutes)
Study NCT00807573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Day 1: Pemetrexed (500 mg/m\^2 over 10 minutes) Day 15 Pemetrexed (500 mg/m2 over 10 minutes)
Study NCT00807573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Day 1:Bevacizumab (10 mg/kg over 20 minutes) Day 15: Bevacizumab (10 mg/kg over 20 minutes)
Study NCT04058171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Treadmill walking test
Description: Participants will be invited to walk on a treadmill at a speed of 1,2 mph for at most five minutes for both conditions (straight walking posture and inclined walking posture). Each walking posture condition will be followed by a rest time of five minutes in sitting position. Conditions were randomized in each group using a computer-generated sequence.
Study NCT02412852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitrite
Description: Sustained release formulation of sodium nitrite
Study NCT01763164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
Study NCT01763164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
Study NCT03883269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin 4% topical gel formulation
Description: Erythromycin 4% topical gel formulation, BID, 4 weeks
Study NCT03883269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 1% topical lotion formulation
Description: Clindamycin 1% topical lotion formulation, BID, 4 weeks
Study NCT03883269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 70% topical ethanol solution
Description: 70% topical ethanol solution, BID, 4 weeks
Study NCT01484964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study NCT00989989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.
Study NCT00989989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Description: Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.
Study NCT00989989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.
Study NCT00989989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham ranibizumab
Description: Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.
Study NCT00989989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham laser photocoagulation
Description: Sham laser treatment administered at day 1.
Study NCT03683602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF group
Description: PNF is used in treatment of musculoskeletal pain of cervical and lumbar spine. Proprioceptive neuromuscular facilitation is a rehabilitation concept widely used by physiotherapists in many countries, in which stimulation of central nervous system is to achieve the highest possible functional level
Study NCT03683602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy group
Description: Manual therapy is used for an assessment and treatment of joint and soft tissues.~The basic therapeutic tool is mobilisation. In the study joint mobilisation according to Kaltenborn-Evjenth Manual Therapy was used. The joint were mobilised with low velocity passive movements in the whole or end range. Spinal manipulation wasn't used. Liter Exelby reports that manual therapy with joints mobilisation was quite effective in improvement of functional movements and decreasing of pain.
Study NCT03384329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol Pill
Description: Resveratrol 500 mg
Study NCT03384329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Pills
Study NCT03609255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing sedentary behavior
Description: Educational handouts for sedentary behavior and strategies reducing sedentary behavior and weekly videos related to reduced sedentary behavior
Study NCT03609255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing stress
Description: Educational handouts for sedentary behavior and stress management handout and weekly videos related stress management
Study NCT03609255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: An educational handout for sedentary behavior and weekly neutral topic videos
Study NCT00712348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Intravenous infusion every 2 weeks
Study NCT03436784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indiana SNAP-Ed
Description: First four Indiana SNAP-Ed nutrition education lessons served as the intervention
Study NCT03124069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Saturn
Description: Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
Study NCT03070743 — intervention group
Intervention type: PROCEDURE
Intervention: Posterior Approach Compression Distraction Reduction Surgery
Description: Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
Study NCT00217464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: intramuscularly
Study NCT00986284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.
Study NCT00169442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™-HepB/Hiberix™ Kft.
Description: GlaxoSmithKline (GSK) Biologicals Korlatolt Felelossegu Tarsasag \[Kft\] (Limited Company) combined diphtheria (D), tetanus (T), whole cell Bordetella pertussis (Pw), hepatitis B vaccine with new sources of D, T and Pw antigens mixed with Haemophilus influenzae type b (Hib2.5) vaccine.
Study NCT00169442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™-HepB/Hiberix™
Description: GSK Biologicals' combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus Influenzae type b vaccine
Study NCT00169442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix™
Description: GSK Biologicals' Haemophilus influenzae type b vaccine
Study NCT00169442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polyribosil-Ribitol-Phosphate (PRP) vaccine
Description: plain PRP polysaccharide vaccine
Study NCT00169442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™-HepB Kft
Description: GSK Biologicals Korlatolt Felelossegu Tarsasag \[Kft\] (Limited Company) combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B vaccine with new sources of D, T and Pw antigens produced at GSK Biologicals Kft., Gödöllö, Hungary.
Study NCT02900144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Comprehensive Behavioral Intervention for Tics
Description: In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
Study NCT02900144 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Behavioral Intervention for Tics
Description: In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
Study NCT00720018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101 Sumatriptan Iontophoretic Transdermal Patch
Description: NP101 transdermal patch delivering sumatriptan for 4 hours.
Study NCT00718562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMN107
Study NCT04242667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Health (web-based) disclosure portal
Description: Patient uses secure web-based portal to access genetic research results
Study NCT04242667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider mediated disclosure
Description: Patient has disclosure of genetic research result by a provider (genetic counselor)
Study NCT02412852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets containing same excipients and coatings used in the active tablets, without sodium nitrite being added.
Study NCT00868374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
Study NCT00868374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
Study NCT03352518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WM3.4NR
Description: The investigational medical device will collect spectral raman data from tissue.
Study NCT02002754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bambuterol Hydrochloride tablets
Description: Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
Study NCT01205425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PCI on the basis of coronary angiography
Description: Interventional cardiologist will be blinded to the images obtained by CT. The PCI procedure will be planned and performed solely on the basis of invasive coronary angiography
Study NCT01205425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT guided PCI
Description: The results of the CT scan will be analysed by the interventional cardiologist that is to perform angiography and PCI. Based on this analysis preliminary procedural strategy is planned (stent diameters, decision on direct stenting vs. predilatation, decision on postdilation)
Study NCT01289262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Purse string closure technique
Description: Uterine incision will be closed with purse string closure technique.
Study NCT01289262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuously locked closure technique
Description: Uterine incision will be closed with continuously locked closure technique
Study NCT00850746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM443
Description: Oral
Study NCT02364063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urotherapy with or without pharmacotherapy
Description: Individualized
Study NCT02364063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: urotherapy with or without pharmacotherapy
Description: Individualized
Study NCT03086187 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hephaistos unloading orthosis
Description: The Hephaistos unloading orthosis greatly reduces plantarflexor muscle torque and plantarflexor muscle activation during any gait activity.
Study NCT00074698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: FG-3019 will be administered per dose and schedule specified in the arm description.
Study NCT00910624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir, 200-mg capsules, 800 mg three times a day (TID) orally (PO)
Study NCT00910624 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (SCH 54031)
Description: Peginterferon alfa-2b 1.5 µg/kg/week subcutaneously (SC)
Study NCT00910624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (SCH 18908)
Description: Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day PO divided twice daily (BID).
Study NCT00850746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT00850746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Oral